Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$125.81 -0.4%	$124.61	$110.04 ▼ $238.00	$18.43B	0.12	1.39 million shs	837,351 shs
INCY Incyte	$64.25 -0.4%	$60.44	$53.56 ▼ $83.95	$12.44B	0.68	2.31 million shs	873,888 shs
IONS Ionis Pharmaceuticals	$32.98 -0.8%	$30.59	$23.95 ▼ $52.34	$5.25B	0.15	1.55 million shs	963,527 shs
UTHR United Therapeutics	$307.65 -0.3%	$299.63	$264.33 ▼ $417.82	$13.88B	0.58	442,728 shs	269,594 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	+0.18%	+5.27%	-10.54%	-44.14%
INCY Incyte	0.00%	+1.48%	+8.95%	-10.83%	+10.40%
IONS Ionis Pharmaceuticals	0.00%	-1.73%	+11.53%	+2.02%	-13.21%
UTHR United Therapeutics	0.00%	+0.75%	+3.79%	-14.80%	+11.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.876 of 5 stars	4.2	5.0	3.7	3.0	2.5	1.9
INCY Incyte	4.8783 of 5 stars	3.1	5.0	3.1	3.5	3.3	3.1
IONS Ionis Pharmaceuticals	4.3856 of 5 stars	4.3	1.0	3.0	3.9	3.3	0.6
UTHR United Therapeutics	4.973 of 5 stars	4.3	3.0	4.6	3.4	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$191.30	52.05% Upside
INCY Incyte	2.17	Hold	$73.53	14.45% Upside
IONS Ionis Pharmaceuticals	2.65	Moderate Buy	$56.67	71.82% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$392.00	27.42% Upside

Current Analyst Ratings Breakdown

Latest IONS, BIIB, UTHR, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/5/2025	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$185.00 ➝ $175.00
5/5/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00
5/2/2025	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$205.00
5/2/2025	BIIB Biogen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$217.00 ➝ $205.00
5/2/2025	BIIB Biogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$265.00 ➝ $220.00
5/2/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$241.00 ➝ $187.00
5/2/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/2/2025	BIIB Biogen	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$300.00 ➝ $255.00
5/1/2025	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $64.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.82B	1.88	$20.66 per share	6.09	$114.71 per share	1.10
INCY Incyte	$4.41B	2.82	$0.50 per share	128.94	$17.82 per share	3.61
IONS Ionis Pharmaceuticals	$717.25M	7.32	N/A	N/A	$3.70 per share	8.91
UTHR United Therapeutics	$2.99B	4.63	$18.50 per share	16.63	$127.35 per share	2.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	11.24	7.62	1.51	16.87%	14.98%	8.76%	8/7/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	237.97	9.82	0.41	0.77%	0.05%	0.04%	7/29/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$366.29M	-$2.99	N/A	N/A	N/A	-64.25%	-100.05%	-15.70%	8/7/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$25.06	13.51	11.19	0.97	40.31%	19.22%	16.15%	7/30/2025 (Estimated)

Latest IONS, BIIB, UTHR, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion
2/26/2025	Q4 2024	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
INCY Incyte	0.01	1.97	1.94
IONS Ionis Pharmaceuticals	2.12	8.47	8.82
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
INCY Incyte	96.97%
IONS Ionis Pharmaceuticals	93.86%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
INCY Incyte	17.80%
IONS Ionis Pharmaceuticals	2.60%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.53 million	146.14 million	Optionable
INCY Incyte	2,320	193.57 million	159.46 million	Optionable
IONS Ionis Pharmaceuticals	800	159.16 million	153.62 million	Optionable
UTHR United Therapeutics	980	45.11 million	39.33 million	Optionable

IONS, BIIB, UTHR, and INCY Headlines

Recent News About These Companies

Q2 EPS Forecast for United Therapeutics Reduced by Analyst

May 25 at 7:31 AM | marketbeat.com

Q3 EPS Estimate for United Therapeutics Reduced by Analyst

May 24 at 7:53 AM | marketbeat.com

Tidal Investments LLC Sells 1,567 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 24 at 4:45 AM | marketbeat.com

ProShare Advisors LLC Trims Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 24 at 4:13 AM | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,342 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 24 at 3:57 AM | marketbeat.com

Zacks Research Analysts Reduce Earnings Estimates for UTHR

May 24 at 2:11 AM | americanbankingnews.com

Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings

May 24 at 1:17 AM | americanbankingnews.com

Liquidia's Yutrepia gets FDA approval for added indication

May 23 at 6:22 PM | msn.com

MidWestOne Financial Group Inc. Increases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 23 at 8:01 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Vident Advisory LLC

May 23 at 6:07 AM | marketbeat.com

Krensavage Asset Management LLC Has $53 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 22 at 7:38 AM | marketbeat.com

Focus Partners Wealth Boosts Position in United Therapeutics Co. (NASDAQ:UTHR)

May 22 at 3:54 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Stake Increased by Soleus Capital Management L.P.

May 21, 2025 | marketbeat.com

Summit Street Capital Management LLC Cuts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

May 20, 2025 | marketbeat.com

Raiffeisen Bank International AG Acquires New Position in United Therapeutics Co. (NASDAQ:UTHR)

May 20, 2025 | marketbeat.com

Rafferty Asset Management LLC Has $13.44 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

May 19, 2025 | marketbeat.com

Nomura Holdings Inc. Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

May 19, 2025 | marketbeat.com

Nuveen Asset Management LLC Cuts Stake in United Therapeutics Co. (NASDAQ:UTHR)

May 19, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Invests $7.80 Million in United Therapeutics Co. (NASDAQ:UTHR)

May 18, 2025 | marketbeat.com

OMERS ADMINISTRATION Corp Has $2.58 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

May 17, 2025 | marketbeat.com

Lazard Asset Management LLC Sells 4,795 Shares of United Therapeutics Co. (NASDAQ:UTHR)

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
By Ryan Hasson | May 5, 2025
View Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
By Thomas Hughes | May 14, 2025
View SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
By Leo Miller | May 19, 2025
View Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
Palantir: AI Leadership and Rising Analyst Expectations
By Chris Markoch | May 20, 2025
View Palantir: AI Leadership and Rising Analyst Expectations

IONS, BIIB, UTHR, and INCY Company Descriptions

Biogen NASDAQ:BIIB

$125.81 -0.49 (-0.39%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$125.81 0.00 (0.00%)

As of 05/23/2025 07:36 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$64.25 -0.26 (-0.40%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$65.72 +1.47 (+2.28%)

As of 05/23/2025 04:29 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Ionis Pharmaceuticals NASDAQ:IONS

$32.98 -0.28 (-0.84%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$32.98 0.00 (-0.02%)

As of 05/23/2025 04:14 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

United Therapeutics NASDAQ:UTHR

$307.65 -1.07 (-0.35%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$302.50 -5.15 (-1.67%)

As of 05/23/2025 04:35 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time